Unfortunately, an FDA policy — specifically the Risk Evaluation and Mitigation Strategies (REMS) program — has been largely ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

(OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative ...

The 2024 Nobel Prizes in physics and chemistry were seen as a sweep for artificial intelligence (AI) tools which, at their ...

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...